<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052697</url>
  </required_header>
  <id_info>
    <org_study_id>C4781001</org_study_id>
    <nct_id>NCT05052697</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza</brief_title>
  <official_title>A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 randomized study to evaluate the safety and immunogenicity of monovalent&#xD;
      influenza modRNA vaccine (mIRV) and bivalent influenza modRNA vaccine (bIRV) at various dose&#xD;
      levels, and quadrivalent influenza modRNA vaccine (qIRV), in participants 65 to 85 years of&#xD;
      age. Participants will receive either:&#xD;
&#xD;
        -  1 of 4 dose levels of mIRV (either A or B Strain),&#xD;
&#xD;
        -  1 of 4 dose levels of bIRV (containing both A and B strains),&#xD;
&#xD;
        -  qIRV, or&#xD;
&#xD;
        -  A licensed quadrivalent influenza vaccine (QIV).&#xD;
&#xD;
      All participants not having received licensed QIV will be offered it 8 weeks after receipt of&#xD;
      study intervention, or as soon as available thereafter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting local reactions</measure>
    <time_frame>For 7 days after vaccination</time_frame>
    <description>Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting systemic events</measure>
    <time_frame>For 7 days after vaccination</time_frame>
    <description>Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self reported in electronic diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events</measure>
    <time_frame>From vaccination to 4 weeks after vaccination</time_frame>
    <description>As elicited by investigational site staff.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants reporting serious adverse events</measure>
    <time_frame>From vaccination to 6 months after vaccination</time_frame>
    <description>As elicited by investigational site staff.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with abnormal hematology and chemistry laboratory values</measure>
    <time_frame>2 days after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with abnormal hematology and chemistry laboratory values</measure>
    <time_frame>1 week after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with grading shifts in hematology and chemistry laboratory assessments</measure>
    <time_frame>Between baseline and 2 days after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with grading shifts in hematology and chemistry laboratory assessments</measure>
    <time_frame>Between baseline and 1 week after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with new electrocardiogram (ECG) abnormalities</measure>
    <time_frame>2 days after vaccination</time_frame>
    <description>ECG abnormalities consistent with probable or possible myocarditis or pericarditis, as judged by a cardiologist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with new ECG abnormalities</measure>
    <time_frame>1 week after vaccination</time_frame>
    <description>ECG abnormalities consistent with probable or possible myocarditis or pericarditis, as judged by a cardiologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) of hemagglutination inhibition (HAI) titers</measure>
    <time_frame>At Baseline, and 1-, 4- and 8-weeks after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in HAI titers from before vaccination to each subsequent timepoint</measure>
    <time_frame>At 1-, 4-, and 8-weeks after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving HAI seroconversion for each strain</measure>
    <time_frame>At 1-, 4-, and 8-weeks after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with HAI titer &gt;=1:40 for each strain</measure>
    <time_frame>At Baseline, and 1-, 4-, and 8-weeks after vaccination</time_frame>
    <description>As measured at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In qIRV and QIV recipients, the proportion of participants achieving HAI seroconversion for all strains</measure>
    <time_frame>At 1-, 4-, and 8-weeks after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In qIRV and QIV recipients, the proportion of participants with HAI titer &gt;=1:40 for all strains</measure>
    <time_frame>At Baseline, and 1-, 4-, and 8-weeks after vaccination</time_frame>
    <description>As measured at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean ratio (GMR) of the geometric mean of HAI titers from participants receiving qIRV to the geometric mean of HAI titers from participants receiving QIV</measure>
    <time_frame>At 4 weeks after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in percentage of participants achieving HAI seroconversion for each strain in qIRV recipients compared to licensed QIV recipients</measure>
    <time_frame>At 4 week after vaccination</time_frame>
    <description>As measured at the central laboratory</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">615</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>mIRV A strain, 3.75 micrograms (ug) dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV A strain, 7.5ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV A strain, 15ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV A strain, 30ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV B strain, 3.75ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV B strain, 7.5ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV B strain, 15ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mIRV B strain, 30ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bIRV 15ug + 15ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bIRV 7.5ug + 7.5ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bIRV 7.5ug + 15ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bIRV 3.75ug + 15ug dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>qIRV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mIRV</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>mIRV A strain, 15ug dose</arm_group_label>
    <arm_group_label>mIRV A strain, 3.75 micrograms (ug) dose</arm_group_label>
    <arm_group_label>mIRV A strain, 30ug dose</arm_group_label>
    <arm_group_label>mIRV A strain, 7.5ug dose</arm_group_label>
    <arm_group_label>mIRV B strain, 15ug dose</arm_group_label>
    <arm_group_label>mIRV B strain, 3.75ug dose</arm_group_label>
    <arm_group_label>mIRV B strain, 30ug dose</arm_group_label>
    <arm_group_label>mIRV B strain, 7.5ug dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bIRV</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>bIRV 15ug + 15ug dose</arm_group_label>
    <arm_group_label>bIRV 3.75ug + 15ug dose</arm_group_label>
    <arm_group_label>bIRV 7.5ug + 15ug dose</arm_group_label>
    <arm_group_label>bIRV 7.5ug + 7.5ug dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>qIRV</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>qIRV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QIV</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>QIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants 65 to 85 years of age.&#xD;
&#xD;
          -  Participants who are willing and able to comply with all scheduled visits, treatment&#xD;
             plan, laboratory tests, lifestyle considerations, and other study procedures.&#xD;
&#xD;
          -  Healthy participants who are determined by medical history, physical examination (if&#xD;
             required), and clinical judgment of the investigator to be eligible for inclusion in&#xD;
             the study.&#xD;
&#xD;
          -  Male participant who is able to father children and willing to use an acceptable&#xD;
             method of contraception; or female participant not of childbearing potential; or male&#xD;
             participant not able to father children.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             of study participation or, in the investigator's judgment, make the participant&#xD;
             inappropriate for the study.&#xD;
&#xD;
          -  History of severe adverse reaction associated with a vaccine and/or severe allergic&#xD;
             reaction (eg, anaphylaxis) to any component of the study intervention.&#xD;
&#xD;
          -  Immunocompromised individuals with known or suspected immunodeficiency, as determined&#xD;
             by history and/or laboratory/physical examination.&#xD;
&#xD;
          -  Bleeding diathesis or condition associated with prolonged bleeding that would, in the&#xD;
             opinion of the investigator, contraindicate intramuscular injection.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Allergy to egg proteins (egg or egg products) or chicken proteins.&#xD;
&#xD;
          -  Participant who has had significant exposure to laboratory-confirmed SARS-CoV-2&#xD;
             infection, COVID-19, or influenza in the past 14 days known prior to Visit 1&#xD;
&#xD;
          -  Any participant who has a SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior&#xD;
             to Visit 1 that has not been confirmed as negative.&#xD;
&#xD;
          -  Individuals who receive treatment with radiotherapy or immunosuppressive therapy,&#xD;
             including cytotoxic agents or systemic corticosteroids, eg, for cancer or an&#xD;
             autoimmune disease, or planned receipt throughout the study.&#xD;
&#xD;
          -  Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60&#xD;
             days before study intervention administration, or planned receipt throughout the&#xD;
             study.&#xD;
&#xD;
          -  Vaccination with any influenza vaccine within 6 months (175 days) before study&#xD;
             intervention administration.&#xD;
&#xD;
          -  Any participant who has received or plans to receive a modRNA-platform SARS-CoV-2&#xD;
             vaccine within 60 days of Visit 1&#xD;
&#xD;
          -  Participation in other studies involving study intervention within 28 days prior to&#xD;
             study entry and/or during study participation.&#xD;
&#xD;
          -  Screening hematology/blood chemistry lab &gt;=Grade 1 abnormality. Except Bilirubin,&#xD;
             other stable Grade1 abnormalities may be considered eligible by Investigator.&#xD;
&#xD;
          -  Screening ECG that is consistent with probable or possible myocarditis or&#xD;
             pericarditis, or demonstrates clinically relevant abnormalities that may affect&#xD;
             participant safety or study results.&#xD;
&#xD;
          -  Investigator site staff or Pfizer employees directly involved in the conduct of the&#xD;
             study, site staff otherwise supervised by the investigator, and their respective&#xD;
             family members.&#xD;
&#xD;
          -  Participation in strenuous or endurance exercise through Visit 3.&#xD;
&#xD;
          -  Prior history of heart disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Heart Rhythm Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Pain Center of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Valley Cardiovascular Center</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92563</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimus U Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>My Cardiologist</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Cardiology, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Group</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associates of Cardiology</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pioneer Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone - Center for the Prevention of Cardiovascular Disease</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital Infectious Disease</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Global Health Research Unit</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbus Cardiovascular Associates, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mt Olympus Medical Research</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Martin Diagnostic Clinic</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Heart Center</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4781001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grippe</keyword>
  <keyword>Flu</keyword>
  <keyword>Influenza</keyword>
  <keyword>Vaccine</keyword>
  <keyword>RNA vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

